ArticleWorld journal of gastroenterology2025
Kushenol I combats ulcerative colitis
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Ameliorative Effect of Erjing Pills on Retinal Damage in Rats with Diabetic Retinopathy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The Structure-Decoding-Conversion-Effect Paradigm of Natural Polysaccharides for Gut Microbiota Remodeling in Ulcerative Colitis.Nutrients · 2026Review
- NGR1 Pretreatment Enhances the Therapeutic Efficacy of Transplanting Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells for Myocardial Infarction.International journal of molecular sciences · 2026Article
- Lung-gut axis, intestinal microbiota, and pulmonary fibrosis: mechanisms and therapeutic potential.Frontiers in microbiology · 2025Review
- Anti-inflammatory effects of natural polysaccharides: molecular mechanisms and nanotherapeutic applications.Frontiers in immunology · 2025Review
- Natural products targeting the MAPK signaling pathway: potential options for ulcerative colitis treatment.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKushenol I (KSCI) exhibits potential anti-inflammatory and antioxidant activities. However, its therapeutic effects and mechanisms in ulcerative colitis (UC) remain unclear.
aimTo investigate the therapeutic effects and mechanisms of KSCI in alleviating UC.
methodsTherapeutic targets for KSCI in treating UC were identified using network pharmacology. Molecular docking and dynamics simulations confirmed the interactions between KSCI and these targets. In a murine UC model induced by dextran sodium sulfate (DSS), the anti-inflammatory and antioxidant effects of KSCI were evaluated following oral administration, as well as its impact on intestinal barrier function and immune response modulation. Finally, changes in gut microbiota composition were analyzed using 16S ribosomal RNA sequencing.
resultsA total of 192 potential targets of KSCI in treating UC were identified using network pharmacology. KSCI bound stably to core targets including protein kinase B (AKT), p38 mitogen-activated protein kinase (p38 MAPK), NOD-like receptor thermal protein domain associated protein 3 (NLRP3), phosphoinositide 3-kinase (PI3K), forkhead box O1 (FOXO1), and Toll-like receptor 4 (TLR4). The oral administration of KSCI improved colon length and body weight, and reduced disease activity in a mouse model of DSS-induced UC. KSCI suppressed pro-inflammatory cytokines (interleukin [IL-1β], IL-6, IL-17, and tumor necrosis factor alpha) and promoted the expression of the anti-inflammatory cytokine IL-10. It also inhibited key signaling molecules and modulated the expression of IL-1β, AKT, p38 MAPK, NLRP3, PI3K, AKT, FOXO1, and TLR4. KSCI exhibited potent antioxidant effects, ameliorating colonic inflammation and tissue damage. It improved intestinal barrier function, influenced gut microbiota composition, and increased splenic T-cell percentages.
conclusionKSCI alleviated DSS-induced UC by modulating gut microbiota, enhancing the intestinal barrier, reducing inflammation and oxidative stress, and regulating the immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.